Recombinant Anti-AMSH antibody [EPR4361] (ab108301)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR4361] to AMSH
- Suitable for: WB
- Knockout validated
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-AMSH antibody [EPR4361]
See all AMSH primary antibodies -
Description
Rabbit monoclonal [EPR4361] to AMSH -
Host species
Rabbit -
Tested applications
Suitable for: WBmore details -
Species reactivity
Reacts with: Human
Predicted to work with: Mouse, Rat -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: Jurkat cell lysate, HeLa cell lysate, HAP1 cell lysate, Raji cell lysate, SW480 cell lysate.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C. -
Storage buffer
pH: 7.20
Preservative: 0.05% Sodium azide
Constituents: 0.1% BSA, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 50% Tissue culture supernatant -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR4361 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
KO cell lines
-
KO cell lysates
-
Positive Controls
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab108301 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/1000 - 1/10000. Predicted molecular weight: 48 kDa.
|
Notes |
---|
WB
1/1000 - 1/10000. Predicted molecular weight: 48 kDa. |
Target
-
Function
Zinc metalloprotease that specifically cleaves 'Lys-63'-linked polyubiquitin chains. Does not cleave 'Lys-48'-linked polyubiquitin chains (By similarity). Functions at the endosome and is able to oppose the ubiquitin-dependent sorting of receptors to lysosomes. Plays a role in signal transduction for cell growth and MYC induction mediated by IL-2 and GM-CSF. Potentiates BMP (bone morphogenetic protein) signaling by antagonizing the inhibitory action of SMAD6 and SMAD7. -
Tissue specificity
Ubiquitously expressed. -
Sequence similarities
Belongs to the peptidase M67C family.
Contains 1 MPN (JAB/Mov34) domain. -
Domain
The JAMM motif is essential for the protease activity. -
Post-translational
modificationsPhosphorylated after BMP type I receptor activation.
Ubiquitinated by SMURF2 in the presence of RNF11. -
Cellular localization
Nucleus. Membrane. Cytoplasm. Early endosome. - Information by UniProt
-
Database links
- Entrez Gene: 10617 Human
- Entrez Gene: 70527 Mouse
- Entrez Gene: 171565 Rat
- Omim: 606247 Human
- SwissProt: O95630 Human
- SwissProt: Q9CQ26 Mouse
- SwissProt: Q8R424 Rat
- Unigene: 469018 Human
see all -
Alternative names
- AMSH antibody
- Associated molecule with the SH3 domain of STAM antibody
- Endosome associated ubiquitin isopeptidase antibody
see all
Images
-
All lanes : Anti-AMSH antibody [EPR4361] (ab108301) at 1/1000 dilution
Lane 1 : Wild-type HeLa lysate
Lane 2 : STAM Binding Protein knockout HeLa lysate
Lane 3 : HAP1 lysate
Lane 4 : Jurkat lysate
Lysates/proteins at 20 µg per lane.
Performed under reducing conditions.
Predicted band size: 48 kDaLanes 1-4: Merged signal (red and green). Green - ab108301 observed at 48 kDa. Red - loading control ab8245 observed at 37 kDa.
ab108301 Anti-STAMBP antibody was shown to specifically react with STAM Binding Protein in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab265249 (knockout cell lysate ab258213) was used. Wild-type and STAM Binding Protein knockout samples were subjected to SDS-PAGE. ab108301 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
-
All lanes : Anti-AMSH antibody [EPR4361] (ab108301) at 1/1000 dilution
Lane 1 : Wild-type HAP1 whole cell lysate
Lane 2 : AMSH knockout HAP1 whole cell lysate
Lane 3 : Jurkat whole cell lysate
Lane 4 : HeLa whole cell lysate
Lysates/proteins at 20 µg per lane.
Predicted band size: 48 kDaLanes 1 - 4: Merged signal (red and green). Green - ab108301 observed at 48 kDa. Red - loading control, ab9484, observed at 37 kDa.
ab108301 was shown to specifically react with AMSH in wild-type HAP1 cells along with additional cross-reactive bands. No band was observed when AMSH knockout samples were examined. Wild-type and AMSH knockout samples were subjected to SDS-PAGE. Ab108301 and ab9484 (Mouse anti GAPDH loading control) were incubated overnight at 4°C at 1/1000 dilution and 1/10000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed ab216773 and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed ab216776 secondary antibodies at 1/10000 dilution for 1 hour at room temperature before imaging.
-
All lanes : Anti-AMSH antibody [EPR4361] (ab108301) at 1/1000 dilution
Lane 1 : Jurkat cell lysate
Lane 2 : HeLa cell lysate
Lane 3 : Raji cell lysate
Lane 4 : SW480 cell lysate
Lysates/proteins at 10 µg per lane.
Performed under reducing conditions.
Predicted band size: 48 kDa
Datasheets and documents
-
SDS download
-
Datasheet download
References (0)
ab108301 has not yet been referenced specifically in any publications.